Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegilodecakin in Advanced Solid Tumors
NCT02009449Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Primary completion
- Feb 2019
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of ilodecakin in solid tumor, melanoma, prostate cancer (PCa) and 6 more (23 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events up to 63 Months and Pharmacokinetic: Serum Concentration of Pegilodecakin at Day 29. Started Nov 2013; status: completed.
02
Drugs
ilodecakin
03
Conditions
solid tumormelanomaprostate cancer (PCa)ovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02009449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02009449.